Winton Group LTD Lineage Cell Therapeutics, Inc. Transaction History

Winton Group LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$1.84 - $2.68 $115,678 - $168,488	-62,869 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$2.26 - $2.86 $20,927 - $26,483	9,260 Added 17.27%	62,869 $158,000
Q2 2021 Aug 10, 2021	BUY	$2.17 - $3.0 $20,823 - $28,788	9,596 Added 21.8%	53,609 $153,000
Q1 2021 Jul 21, 2021	BUY	$1.77 - $3.1 $16,358 - $28,650	9,242 Added 26.58%	44,013 $103,000
Q4 2020 Feb 12, 2021	SELL	$0.95 - $1.83 $31,122 - $59,952	-32,761 Reduced 48.51%	34,771 $61,000
Q3 2020 Oct 30, 2020	SELL	$0.75 - $1.09 $30,561 - $44,415	-40,748 Reduced 37.63%	67,532 $63,000
Q2 2020 Aug 05, 2020	SELL	$0.71 - $1.18 $7,565 - $12,572	-10,655 Reduced 8.96%	108,280 $94,000
Q1 2020 May 11, 2020	SELL	$0.6 - $1.58 $24,249 - $63,857	-40,416 Reduced 25.36%	118,935 $98,000
Q4 2019 Feb 13, 2020	BUY	$0.54 - $1.01 $86,049 - $160,944	159,351 New	159,351 $142,000

134

106M

22.1K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $115M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.